NCT06791772 - Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

CM313 injection

CM313 600mg（4ml）/vial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.

BIOLOGICAL

CM313 injection

CM313 600mg（4ml）/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.

DRUG

Placebo

Placebo 4 mL/vial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.

Trial Locations (1)

Peking Union Medical College Hospital, Beijing